Effect of Repeated Administration of Liraglutide on Insulinogenic Indices

NCT02089256 · Completed

Last updated 2026-05-28

This clinical trial tested how repeated doses of the medication liraglutide affect insulin production in healthy individuals.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 10 people

Who can join Ages 18–50 · all sexes Healthy volunteers accepted.

Timeline Started 2014-06 · est. completion 2015-03

Where 1 site · Estonia

What this study is testing ClinicalTrials.gov NCT02089256 ↗

Description as written by the study sponsor.

The study investigates the effect of glucagon-like peptide receptor 1 agonist, liraglutide, on insulin secretion. Study hypothesis: the effect of liraglutide on insulin release may change after repeated administration. The effect of liraglutide on insulin release will be tested using graded glucose infusion test (GGIT) in healthy volunteers. GGIT will be performed without medication and repeated 12 hours after first dose of liraglutide and after 3 weeks of treatment with liraglutide.

Treatments tested

Liraglutide also known as Victoza Drug

Graded glucose infusion test (GGIT)will be performed on baseline. 1 week later treatment with liraglutide 0.6mg/day (injected between 21.00-23.00) will be initiated. GGIT will be repeated 12 hours after first injection and after 21 days on-treatment (12 hours after last injection).

Main thing measured	Change in the glucose-sensitivity of the beta cells
Sponsor	University of Tartu
Conditions studied	Healthy
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02089256 ↗